ProQR Therapeutics Nominates Dr. Lykke Hinsch Gylvin to Board of Directors

On April 30, 2026, ProQR Therapeutics N.V. announced the nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors as an independent non-executive director. Dr. Hinsch Gylvin currently serves as the Chief Medical Officer and Head of Global Medicine at Boehringer Ingelheim, where she oversees global medical and clinical development across various therapeutic areas including oncology, immunology, and rare diseases. Her extensive background includes senior leadership positions at Novartis, AstraZeneca, Roche, and Novo Nordisk. The nomination is subject to shareholder approval at the company's upcoming Annual General Meeting. ProQR is a clinical-stage biotechnology company focused on transformative RNA therapies using its proprietary Axiomer RNA editing technology platform. The addition of Dr. Hinsch Gylvin is expected to strengthen the Board's expertise in global drug development and regulatory strategy as the company advances its pipeline of RNA-based medicines.